Clostridium difficile Infections Treatment Landscape Discussed by GlobalData in Its Topical Research Report Available at MarketPublishers.com

01 Nov 2017 • by Natalie Aster

LONDON – Since 2000, C. difficile infections (CDIs) have become increasingly commonplace, more severe and difficult to treat utilising present-day therapies, and more likely to be recurrent than in earlier times. These realities, in tandem with the growing threat of antibiotic resistance, emphasises the significance of developing CDI-specific treatment options and launching them on the market.

Over the next decade, there are 9 products that are in the way of being launched, which will likely contribute to significant growth in the market. The launch of the first prophylactic measures to prevent CDIs, starting from Sanofi Pasteur’s vaccine ACAM-CDIFF in 2019, is poised to meet a key unmet need, as well as exert a huge influence on the overall size of the CDI marketplace. The anticipated launch of the first microbiological therapies, leveraging the effectiveness associated with FMT pertaining to the rates of recurrence for CDI, will also likely impact the total treatment landscape in the offing. By 2026, antibiotics are anticipated to remain the super-lucrative product class in the CDI marketplace, with new vaccines also grabbing a formidable market share.

Topical research study “OpportunityAnalyzer: Clostridium difficile Infections - Opportunity Analysis and Forecasts to 2026” drawn up by GlobalData offers a detailed analysis of the world’s CDI market landscape and dynamics across the 7MM – the USA, 5 European countries and Japan.

It provides a deep dive into the disease, covering etiology, epidemiology, pathophysiology, diagnosis, symptoms and present-day management. It provides top-line CDI market revenue through to 2026, includes data on the annual cost of therapy and key pipeline product sales over the projected period.

The study examines existing treatment modes, unmet needs, opportunities existing for products proven to be cost-effective as against SoC antibiotics, and the driving and limiting factors impacting the sales of CDI therapeutics and prophylactics in the 7MM. It breaks down the data across various phases, keeps track of the emerging new trends under development, gives capsule reviews of innovative projects at an early-stage, and offers a granular analysis of products in the late-stage pipeline. Furthermore, the publication explores the actual and future market competition in the world market for CDI therapeutics and prophylactics. The report offers an insightful assessment of the main industry drivers & limiters and major challenges. Each trend is studied independently to give a qualitative analysis of its implications.

Many other topical reports by GlobalData are available in the publisher’s online catalogue at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com